TR200301062T2 - Adenosin reseptörü antagonistleri ve bu antagonistlerin yapım ve kullanım yöntemleri - Google Patents

Adenosin reseptörü antagonistleri ve bu antagonistlerin yapım ve kullanım yöntemleri

Info

Publication number
TR200301062T2
TR200301062T2 TR2003/01062T TR200301062T TR200301062T2 TR 200301062 T2 TR200301062 T2 TR 200301062T2 TR 2003/01062 T TR2003/01062 T TR 2003/01062T TR 200301062 T TR200301062 T TR 200301062T TR 200301062 T2 TR200301062 T2 TR 200301062T2
Authority
TR
Turkey
Prior art keywords
production
receptor antagonists
adenosine receptor
use methods
adenosine
Prior art date
Application number
TR2003/01062T
Other languages
English (en)
Inventor
E. Dowling James
L. Ensinger Carol
Kumaravel Gnanasambandam
C. Petter Russell
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of TR200301062T2 publication Critical patent/TR200301062T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Bulus, (I) Formülü bilesiklerinin, adenosin A1 reseptörünün beklenmedik sekilde yüksek ölçüde kuvvetli ve seçici inhibitörleri oldugundan kesfine dayanmaktadir. Adenosin A1 antagonistleri, kardiyak ve dolasim bozukluklari, merkezi sinir sisteminin dejeneratif bozukluklari, solunum bozukluklari ve diüretik tedavinin müsait oldugu bir çok hastaliklari kapsayan çesitli hastaliklarin engellenmesinde ve/veya iyilestirilmesinde yararli olabilmektedir. Bir düzenlemede, bulus, (I) formülünün bir bilesigine iliskindir.
TR2003/01062T 1999-11-12 2000-11-13 Adenosin reseptörü antagonistleri ve bu antagonistlerin yapım ve kullanım yöntemleri TR200301062T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16528399P 1999-11-12 1999-11-12

Publications (1)

Publication Number Publication Date
TR200301062T2 true TR200301062T2 (tr) 2003-09-22

Family

ID=22598257

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2003/01062T TR200301062T2 (tr) 1999-11-12 2000-11-13 Adenosin reseptörü antagonistleri ve bu antagonistlerin yapım ve kullanım yöntemleri

Country Status (33)

Country Link
US (4) US6605600B1 (tr)
EP (2) EP1230241B1 (tr)
JP (1) JP2003513976A (tr)
KR (1) KR100845488B1 (tr)
CN (1) CN1187354C (tr)
AT (1) ATE353328T1 (tr)
AU (1) AU784528B2 (tr)
BG (1) BG106693A (tr)
BR (1) BR0015540A (tr)
CA (1) CA2390590C (tr)
CY (1) CY1106560T1 (tr)
CZ (1) CZ20021615A3 (tr)
DE (1) DE60033310T2 (tr)
DK (1) DK1230241T3 (tr)
EA (1) EA010260B1 (tr)
EE (1) EE200200248A (tr)
ES (1) ES2281367T3 (tr)
GE (1) GEP20043267B (tr)
HK (1) HK1049153B (tr)
HU (1) HUP0203371A3 (tr)
IL (1) IL149486A0 (tr)
IS (1) IS6380A (tr)
MX (1) MXPA02004795A (tr)
NO (1) NO20022237L (tr)
NZ (2) NZ519427A (tr)
PL (1) PL198156B1 (tr)
PT (1) PT1230241E (tr)
SK (1) SK6622002A3 (tr)
TR (1) TR200301062T2 (tr)
UA (1) UA77937C2 (tr)
WO (1) WO2001034604A2 (tr)
YU (1) YU33702A (tr)
ZA (1) ZA200203702B (tr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
EP2305684A1 (en) * 1999-11-12 2011-04-06 Biogen Idec MA Inc. Poycyloalkylpurines as adenosine receptor antagonists
CA2390590C (en) * 1999-11-12 2010-03-16 Biogen, Inc. Adenosine receptor antagonists and methods of making and using the same
UA84404C2 (ru) * 2002-06-12 2008-10-27 Байоджен Айдек Ма Инк. Способ лечения ишемического реперфузионного повреждения с помощью антагонистов рецептора аденозина
WO2004009594A2 (en) * 2002-07-19 2004-01-29 Aryx Therapeutics Xanthine derivatives having adenosine a1-receptor antagonist properties
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
MXPA05011070A (es) * 2003-04-14 2005-12-12 Pfizer Prod Inc Derivados de 3-azabiciclo [3.2.1] octano.
EP1620107A1 (en) * 2003-04-25 2006-02-01 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
EP1636229A4 (en) * 2003-06-06 2008-07-30 Endacea Inc ADENOSINE A1 RECEPTOR ANTAGONISTS
US20070208040A1 (en) * 2006-03-02 2007-09-06 Elfatih Elzein A2a adenosine receptor antagonists
CA2648281A1 (en) * 2006-04-06 2007-10-18 Novacardia, Inc. Co-administration of adenosine a1 receptor antagonists and anticonvulsants
US7872017B2 (en) 2006-05-19 2011-01-18 Abbott Laboratories Fused bicycloheterocycle substituted azabicyclic alkane derivatives
JP2009540003A (ja) * 2006-06-16 2009-11-19 ノヴァカーディア，インク． Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
WO2008121893A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
US20090228097A1 (en) * 2008-03-07 2009-09-10 Abbott Cardiovascular Systems Inc. A1 Adenosine Receptor Antagonist-Coated Implantable Medical Device
CN114790164B (zh) 2021-08-13 2022-12-27 苏州璞正医药有限公司 一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155664A (en) * 1959-11-13 1964-11-03 Endo Lab Derivatives of theophylline
DE8817122U1 (de) 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US5290782A (en) 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
EP0423805B1 (en) 1989-10-20 2000-08-23 Kyowa Hakko Kogyo Kabushiki Kaisha Condensed purine derivatives
DE4019892A1 (de) 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
CA2061544A1 (en) 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
CA2082325A1 (en) 1991-11-08 1993-05-09 Fumio Suzuki Xanthine derivatives
JPH05294966A (ja) 1992-02-17 1993-11-09 Kyowa Hakko Kogyo Co Ltd キサンチン誘導体
US5342841A (en) 1992-03-12 1994-08-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
TW252044B (tr) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
WO1994016702A1 (fr) 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Medicament contre l'elimination irreguliere des matieres fecales
JP3729874B2 (ja) * 1993-04-07 2005-12-21 協和醗酵工業株式会社 キサンチン誘導体
US5395836A (en) 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
AU7675498A (en) 1997-06-16 1999-01-04 Kyowa Hakko Kogyo Co. Ltd. Preventive and remedy for drug-induced nephropathy
WO1998057645A1 (en) 1997-06-16 1998-12-23 Kyowa Hakko Kogyo Co., Ltd. Hepatic edema remedy
DE19816857A1 (de) 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0955301A3 (en) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
AU4396899A (en) 1998-07-02 2000-01-24 Kyowa Hakko Kogyo Co. Ltd. Remedies for diabetes
CA2390590C (en) * 1999-11-12 2010-03-16 Biogen, Inc. Adenosine receptor antagonists and methods of making and using the same
EP2305684A1 (en) * 1999-11-12 2011-04-06 Biogen Idec MA Inc. Poycyloalkylpurines as adenosine receptor antagonists

Also Published As

Publication number Publication date
EP1230241A2 (en) 2002-08-14
US20030225038A1 (en) 2003-12-04
GEP20043267B (en) 2004-06-25
MXPA02004795A (es) 2005-07-01
DE60033310D1 (de) 2007-03-22
EP1775297A3 (en) 2008-12-03
BR0015540A (pt) 2002-07-23
UA77937C2 (en) 2007-02-15
DE60033310T2 (de) 2007-11-22
EP1775297A2 (en) 2007-04-18
WO2001034604A2 (en) 2001-05-17
HK1049153B (en) 2007-09-28
AU2042101A (en) 2001-06-06
YU33702A (sh) 2005-03-15
ATE353328T1 (de) 2007-02-15
US6605600B1 (en) 2003-08-12
EP1230241B1 (en) 2007-02-07
EA200200562A1 (ru) 2002-10-31
ZA200203702B (en) 2003-10-29
US20080004293A1 (en) 2008-01-03
US20050222179A1 (en) 2005-10-06
JP2003513976A (ja) 2003-04-15
HUP0203371A2 (hu) 2003-02-28
AU784528B2 (en) 2006-04-27
EA010260B1 (ru) 2008-06-30
NZ519427A (en) 2003-08-29
HUP0203371A3 (en) 2005-02-28
NO20022237D0 (no) 2002-05-10
HK1049153A1 (en) 2003-05-02
KR100845488B1 (ko) 2008-07-10
CA2390590A1 (en) 2001-05-17
ES2281367T3 (es) 2007-10-01
IL149486A0 (en) 2002-11-10
PL356044A1 (en) 2004-06-14
CY1106560T1 (el) 2012-01-25
CN1399636A (zh) 2003-02-26
DK1230241T3 (da) 2007-06-04
PL198156B1 (pl) 2008-05-30
NZ527918A (en) 2005-05-27
WO2001034604A3 (en) 2002-01-10
CZ20021615A3 (cs) 2002-08-14
EE200200248A (et) 2003-06-16
IS6380A (is) 2002-05-10
PT1230241E (pt) 2007-05-31
KR20020049043A (ko) 2002-06-24
CN1187354C (zh) 2005-02-02
NO20022237L (no) 2002-07-12
BG106693A (bg) 2003-01-31
SK6622002A3 (en) 2003-02-04
CA2390590C (en) 2010-03-16

Similar Documents

Publication Publication Date Title
YU33802A (sh) Policikloalkilpurini kao antagonisti adenozinskih receptora
TR200301062T2 (tr) Adenosin reseptörü antagonistleri ve bu antagonistlerin yapım ve kullanım yöntemleri
TR199700749T1 (tr) 5-HT reseptör antagonisti olarak indole türevleri.
TNSN05045A1 (en) Indole or benzimidazole derivatives for modulating ikappab kinase
ATE234322T1 (de) A1 adenosin rezeptor agonisten und antagonisten
TR200300766T2 (tr) A1 adenosin reseptörü antagonistleri olarak yoğunlaştırılmış purin türevleri.
NO20023362D0 (no) 1,2-diarylbenzimidazoler for behandling av sykdommer assosiert med en mikrogliaaktivering
ATE286883T1 (de) Isochinolin und chinazolinderivate mit kombinierter 5ht1a, 5ht1b und 5ht1d rezeptor aktivität
ATE236134T1 (de) Isoquinolinamin und phtalazinamin derivate, die reagieren mit crf rezeptoren
BR9406034A (pt) Derivados de imidazoloquinoxalinonas como antagonistas de eaa.